Clinical trial of indomethacin in Alzheimer's disease
J Rogers, LC Kirby, SR Hempelman, DL Berry… - Neurology, 1993 - AAN Enterprises
J Rogers, LC Kirby, SR Hempelman, DL Berry, PL McGeer, AW Kaszniak, J Zalinski…
Neurology, 1993•AAN EnterprisesIn a 6-month, double-blind, placebo-controlled study, 1100 to 150 mg/d indomethacin
appeared to protect mild to moderately impaired Alzheimer's disease patients from the
degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a
battery of cognitive tests, indomethacin patients improved 1.3%(±1.8%), whereas placebo
patients declined 8.4%(±2.3%)—a significant difference (p< 0.003). Caveats include
adverse reactions to indomethacin and the limited scale of the trial.
appeared to protect mild to moderately impaired Alzheimer's disease patients from the
degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a
battery of cognitive tests, indomethacin patients improved 1.3%(±1.8%), whereas placebo
patients declined 8.4%(±2.3%)—a significant difference (p< 0.003). Caveats include
adverse reactions to indomethacin and the limited scale of the trial.
In a 6-month, double-blind, placebo-controlled study, 1100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer's disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (±1.8%), whereas placebo patients declined 8.4% (±2.3%)—a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.
American Academy of Neurology